ORMP Dividend: Oramed Pharmaceuticals Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

ORMP Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	08/31/2021
Revenue	2	0	1	2	0	2
Revenue Growth (YoY)	--	-100%	-50%	--	-100%	0%
Cost of Revenue	1	--	--	--	--	--
Gross Profit	0	--	--	--	--	--
Selling, General & Admin	6	6	8	15	4	5
Research & Development	6	6	8	27	9	20
Operating Expenses	13	12	17	43	13	26
Other Non Operating Income (Expenses)	0	1	-1	0	--	0
Pretax Income	-22	-15	5	-37	-12	-22
Income Tax Expense	2	3	0	0	--	0
Net Income	-24	-19	5	-36	-11	-22
Net Income Growth	-220%	-480%	-113.99%	227%	-50%	100%
Shares Outstanding (Diluted)	42.6	40.82	40.56	39	37.11	28.47
Shares Change (YoY)	2%	1%	4%	5%	30%	39%
EPS (Diluted)	-0.56	-0.46	0.13	-0.94	-0.31	-0.78
EPS Growth	-212%	-443%	-113.99%	199%	-60%	39%
Free Cash Flow	-16	-8	-10	-28	-11	-21
Free Cash Flow Per Share	-0.37	-0.19	-0.24	-0.71	-0.29	-0.73
Gross Margin	0%	--	--	--	--	--
Operating Margin	-650%	0%	-1,500%	-2,000%	0%	-1,200%
Profit Margin	-1,200%	0%	500%	-1,800%	0%	-1,100%
Free Cash Flow Margin	-800%	0%	-1,000%	-1,400%	0%	-1,050%
EBITDA	-13	-12	-15	-40	-12	-24
EBITDA Margin	-650%	0%	-1,500%	-2,000%	0%	-1,200%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-13	-12	-15	-40	-12	-24
EBIT Margin	-650%	0%	-1,500%	-2,000%	0%	-1,200%
Effective Tax Rate	-9.09%	-20%	0%	0%	--	0%